CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Castle Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Castle Biosciences Inc
505 S Friendswood Drive
2014 SAN MIGUEL DR
Phone: (281) 796-9032p:281 796-9032 FRIENDSWOOD, TX  77546  United States Ticker: CSTLCSTL
Business Summary
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8071 Medical laboratories
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Daniel M.Bradbury 62 9/1/2014 9/1/2012
President, Chief Executive Officer, Founder, Director Derek J.Maetzold 61 9/1/2007 9/1/2007
Chief Financial Officer FrankStokes 53 12/1/2017 12/1/2017
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
AltheaDx Inc 3030 Bunker Hill Street San Diego CA United States
Cernostics, Inc. 235 William Pitt Way Pittsburgh PA United States

Business Names
Business Name
AltheaDx Inc
AltheaDx, Inc.
Castle Narnia Way Real Estate Holding 1, LLC
Cernostics, Inc.
CSTL
Myriad myPath, LLC

General Information
Number of Employees: 610 (As of 12/31/2023)
Outstanding Shares: 27,587,062 (As of 4/2/2024)
Shareholders: 132
Stock Exchange: NASD
Federal Tax Id: 770701774
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024